Literature DB >> 16360004

Brief communication: a new combination in the treatment of advanced pancreatic cancer.

Malcolm J Moore1.   

Abstract

Single-agent gemcitabine is currently the standard treatment for advanced pancreatic cancer. A majority of recent phase III trials have shown either marginal or no improvement in survival using gemcitabine in combination with other chemotherapeutic and novel agents. Our group recently reported that the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival and improvement in progression-free survival in advanced pancreatic cancer.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16360004     DOI： 10.1053/j.seminoncol.2005.07.017

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  10 in total

1.  Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Authors:  Maria C Villarroel; N V Rajeshkumar; Ignacio Garrido-Laguna; Ana De Jesus-Acosta; Siân Jones; Anirban Maitra; Ralph H Hruban; James R Eshleman; Alison Klein; Daniel Laheru; Ross Donehower; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-12-06       Impact factor: 6.261

Review 2.  The Microbiome in Pancreatic Cancer-Implications for Diagnosis and Precision Bacteriophage Therapy for This Low Survival Disease.

Authors:  Mwila Kabwe; Stuart Dashper; Joseph Tucci
Journal:  Front Cell Infect Microbiol       Date:  2022-05-19       Impact factor: 6.073

3.  Human amniotic fluid mesenchymal stem cells attenuate pancreatic cancer cell proliferation and tumor growth in an orthotopic xenograft mouse model.

Authors:  Ying-Cheng Chen; Ying-Wei Lan; Shiaw-Min Huang; Chih-Ching Yen; Wei Chen; Wan-Ju Wu; Theresa Staniczek; Kowit-Yu Chong; Chuan-Mu Chen
Journal:  Stem Cell Res Ther       Date:  2022-06-03       Impact factor: 8.079

4.  The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.

Authors:  Meredith A Morgan; Leslie A Parsels; Laura E Kollar; Daniel P Normolle; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 5.  Pancreatic cancer.

Authors:  Anirban Maitra; Ralph H Hruban
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

6.  FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.

Authors:  Weiguo Liu; David A Bloom; William G Cance; Elena V Kurenova; Vita M Golubovskaya; Steven N Hochwald
Journal:  Carcinogenesis       Date:  2008-02-07       Impact factor: 4.944

Review 7.  TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment.

Authors:  Mai Abdel Mouti; Siim Pauklin
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

8.  Hepatic arterial therapy with drug-eluting beads in the management of metastatic pancreatic carcinoma to the liver: a multi-institutional registry.

Authors:  Raffi Kotoyan; Tiffany Metzger; Cliff Tatum; Ken Robbins; Robert C G Martin
Journal:  J Oncol       Date:  2012-02-15       Impact factor: 4.375

9.  Pancreatic cancer: challenges and opportunities.

Authors:  Huiyun Zhu; Tuo Li; Yiqi Du; Min Li
Journal:  BMC Med       Date:  2018-11-22       Impact factor: 8.775

Review 10.  EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

Authors:  G Milano; J-P Spano; B Leyland-Jones
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.